Summary Beam Therapeutics announced updated biomarker data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel), reinforcing its position as the leading base-edited cell therapy program in sickle cell disease ahead of a planned BLA submission by year-end 2026.…
Summary Agios Pharmaceuticals submitted a supplemental NDA to the FDA seeking accelerated approval of mitapivat for sickle cell disease, positioning the oral PKR activator in a highly competitive emerging therapeutic class. What Happened Agios submitted its sNDA for mitapivat in…
Summary Incyte announced more than 20 hematology and oncology presentations for EHA 2026, highlighted by plenary Phase 3 frontMIND data in frontline diffuse large B-cell lymphoma (DLBCL) and new clinical data for INCA033989, a mutation-specific antibody targeting mutant calreticulin in…
Summary Johnson & Johnson announced more than 30 hematology presentations for EHA 2026, including key datasets from the Phase 3 MonumenTAL-3 and MajesTEC-9 multiple myeloma studies and pivotal Phase 2/3 ENERGY data for IMAAVY in warm autoimmune hemolytic anemia. What…
Summary Inhibrx Biosciences reported interim Phase 2 data for INBRX-106 in combination with Keytruda in first-line head and neck squamous cell carcinoma (HNSCC), suggesting potential costimulatory benefit beyond PD-1 monotherapy. What Happened The company released early Phase 2 clinical data…
Summary Novo Nordisk has transferred a Parkinson’s disease cell therapy program to Cellular Intelligence, reflecting continued asset recycling and lifecycle extension within the advanced cell therapy ecosystem. What Happened Cellular Intelligence, an AI-focused biotechnology company, acquired rights to a discontinued…
Summary Fractyl Health has received authorization in the Netherlands to initiate the first-in-human clinical trial of RJVA-001, an AAV-based gene therapy for type 2 diabetes, marking the first clinical-stage gene therapy program targeting the disease. What Happened The Dutch regulatory…
Summary GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction. What Happened GSK agreed to pay SiranBio $55 million…
Summary CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development. What Happened The financing will fund late-stage clinical development…
Company Takeda Pharmaceutical (Osaka / Cambridge, MA) Event Type Phase 2/3 pivotal trial topline results — primary endpoint met Modality Plasma-derived immunoglobulin SC with recombinant human hyaluronidase Target IgG replacement / immune reconstitution Indication Primary Immunodeficiency Disease (PID) — adults…
